HitGen Inc. announced that it has entered into a partnership with The Structural Genomics Consortium (SGC). HitGen will utilize its DNA-encoded library (DEL) technology platform, specifically OpenDEL?, to screen under-represented targets chosen by SGC. The screening datasets, curated in a ML-ready format, will be posted to a publicly accessible portal to facilitate drug discovery and ML experts from around the world to model the data and make predictions about new active molecules that would be experimentally tested at SGC as part of the Target 2035 initiative.

OpenDEL? is a self-service DEL kit with over 3 billion compounds, which enables users to explore DEL selection campaigns without revealing the target identity. Under the guidance of the manual and operating instructions, users can utilize OpenDEL?

to conduct affinity screening experiments against protein targets in their own laboratories. HitGen can provide upstream and downstream technical support.